Compare Merck & Co., Inc. (MRK) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Nuscale Power Corporation — how do they compare? Merck & Co., Inc. trades at $147.98 (market cap $363.98B), while Nuscale Power Corporation trades at $10.81 (market cap $4.44B). The key difference: Merck & Co., Inc. is far larger — about 82× Nuscale Power Corporation's market cap, and Merck & Co., Inc. pays a 2.3% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals.
| MRK | SMR | |
|---|---|---|
Market Cap | $363.98B | $4.44B |
Sector | Health | Utilities |
52-Week High | $156.43 | $53.43 |
52-Week Low | $77.60 | $7.59 |
Enterprise Value | $410.75B | $3.36B |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
SMR stock trades at $11.18, up 15.32% in the last 24 hours, with a bullish technical signal from moving averages and oscillators. The company reported a net loss of $355.79 million on $31.48 million revenue in 2025, with a negative net income margin of -3,888.7% and a high price-to-sales ratio of 272.59. Recent news highlights its cash position and potential in small modular reactors for AI energy demand.
Outlook is speculative with high growth potential from nuclear energy trends but significant execution risks. Analysts are divided, with a 50% buy rating and $11.25 consensus target. Key risks include cash burn, lack of profitability, and project delays, requiring cautious investor consideration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
